Latest Commercial Operations News

Alexium International Group reported a challenging Q3 FY2025 with lower revenues due to softness in the US bedding market, while making significant technological strides and maintaining a solid funding position.

Streamplay Studio Limited reported a remarkable 827% increase in customer receipts for Q3 2025, driven by the full integration of Noodlecake Studios. With a robust cash balance of A$7.7 million and no debt, the company is well-positioned to accelerate growth across cloud gaming, game publishing, and emerging markets.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Invictus Energy has secured Environmental and Social Impact Assessment approval for pilot gas production at its Cabora Bassa Project, unlocking the path to commercial gas extraction and power generation in Zimbabwe.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

WAT Resources Ltd has successfully produced ferroniobium from its Luni niobium concentrate, marking a key milestone in the West Arunta Project’s development. The proof-of-concept testwork confirms the viability of a conventional production process and sets the stage for further optimisation and product diversification.

Ten Sixty Four Limited’s latest quarterly report reveals a notable decline in gold production alongside increased all-in sustaining costs, as the company advances its mine development and navigates a complex restructuring process.

MPower Group has finalized the conversion of a $10 million project funding facility for its Narromine Renewable Energy Project into equity, with AMPYR Distributed Energy acquiring full ownership. The move strengthens MPower's balance sheet and supports its strategic push into hybrid renewable assets.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Pure Hydrogen advances its zero-emission vehicle strategy with key deliveries, US partnerships, and a planned demerger of its natural gas assets into Eastern Gas Limited.

Clever Culture Systems Ltd has achieved a key cashflow break-even milestone in Q4 2024, driven by strong sales growth from major pharmaceutical clients including AstraZeneca and Bristol Myers Squibb. The company is also advancing its product line with a new APAS® Contact Plate capability set for mid-2025 launch.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.